Terrell Herring leverages over 30 years of experience in the pharmaceutical industry to serve as president of commercial operations at Mission Pharmacal, where he develops strategy and plays a key role in decisions ranging from new product offerings to upper-level hiring and placements. Terrell Herring’s pharmaceutical experience also assists him in other professional endeavors, including his service on the Advisory Board of BioAgilytix. With headquarters in Hamburg, Germany, and Durham, North Carolina, BioAgilytix is a biological testing laboratory that specializes in large molecule bioanalysis. Its team comprises scientific and QA professionals who provide a wide range of bioanalytical services to assist clients at every phase of the study process, from preclinical and discovery work to phase I through phase IV trials, ensuring regulatory compliance each step of the way. One of the company’s many services is pharmacokinetics assessment. Pharmacokinetics (PK) focuses on the human body’s reaction to a given pharmaceutical, from ingestion through absorption, distribution, metabolism, and ultimately excretion. PK assessment of a given pharmaceutical helps shed light on its efficacy as well as its interaction with the body, and assists pharmaceutical companies in determining drug safety and dosage specifications. BioAgilytix provides PK assessment support across a range of species studies and in multiple formats, such as plasma, urine, saliva, and serum.
0 Comments
Terrell Herring is an executive serving dual roles as commercial operations president of San Antonio, Texas-based Mission Pharmacal and president of its subsidiary, Alamo Pharma Services in Doylestown, Pennsylvania. He holds has a bachelor’s degree in biology and post-graduate certificates in project design and international marketing. Terrell Herring brings his wide-ranging interests and adaptability to his charitable activities, which include past participation in Big Brothers Big Sisters of America and the American Red Cross, as well as his current participation as a member of the board of directors for Bridging the Gap Africa (BtGA). Headquartered in Bowling Green, Ohio, Bridging the Gap Africa (BtGA) is a non-profit organization that helps rural communities in Kenya build footbridges to prevent drowning and provide safe access to work, school, and healthcare. Founded in 1997 by Harmon Parker, who was named a Top 10 CNN Hero in 2010, BtGA has since constructed more than 46 footbridges in rural Kenya. These footbridges have provided more than one million safe crossings over 15 years, transforming the lives of community residents and paving the way for a better future through access to education and economic opportunity. According to its website, BtGA provides technical and financial assistance for bridge construction and helps community leaders in organize local volunteers to gather sand and rock for bridge footings. BtGA commissions bridges at project completion and hosts celebrations to recognize the community’s achievement. Earlier this year, BtGA announced a ground-breaking footbridge to be known as Kakenya’s Crossing. More than $42,000 in funding for the bridge was raised in 2016 through charitable contributions. As the current president of commercial operations for San Antonio-based Mission Pharmacal Company, Terrell “Terry” Herring has served as a senior executive for over seven years. As a successful businessman, Terrell “Terry” Herring has also served as a board member of several organizations, including the board of directors for Bridging the Gap Africa. Bridging the Gap Africa is an organization that helps to build secure and safe footbridges in Africa to help communities with safer river and canyon crossings. The footbridges help children to safely reach schools, as well as provide safe access to healthcare in local communities and help to prevent deaths from accidental drownings as well as attacks from crocodiles and hippos. Bridging the Gap Africa began with its first bridge in Kenya in 1997. Since that time, the organization has been responsible for building more than 46 footbridges in Kenya. Bridging the Gap Africa is a nonprofit organization that operates from the donations of individuals and companies. With close to two decades of experience in senior leadership roles, Terrell (“Terry”) Herring serves as the president of commercial operations for Mission Pharmacal. A focused, driven person, he has endeavored to help others achieve their potential, whether at work, coaching children’s soccer, as an Archway Advisory Board member, or guiding youth as a Camp Kirkwood Board member. Terrell Herring earned his BS in biology, graduating magna cum laude, from The Citadel, The Military College of South Carolina. Ranked by U.S. News & World Report for the sixth consecutive year as the No. 1 Public Regional University in the South, The Citadel has 2,300 students that comprise the South Carolina Corps of Cadets. Additionally, there are 1,200 students enrolled in The Citadel Graduate College. The Corps of Cadets experiences college life under a traditional military arrangement where leadership and character building are an integral component of their education. Leadership and ethics studies are compulsory, providing real-life leadership trials. Cadets participate in the mandatory, annual Leadership Day, providing over 7,500 hours of volunteer community service. The program incorporates involved collaborations with 36 community organizations from the Lowcountry, including students from schools where poverty is high and test scores alarmingly low. The Citadel belongs to the 2 percent of schools that hold the distinction of being one of America’s most civic-minded colleges under the Carnegie Foundation’s Community Engagement Classification. Before his career in pharmaceutical sales management, Terrell “Terry” Herring attended The Citadel, Military College of South Carolina in Charleston where he earned a bachelor of science degree in biology. Terrell “Terry” Herring also attended Duke University/London Fuqua School of Business where he earned a graduate certificate in international marketing.
A global business school connected with Duke University, the Fuqua School of Business in London, England offers a graduate program in international marketing. The international program caters to students with an interest in marketing and focuses on customer assets and developing good stewardship of firm brand equity. The marketing program includes training in product management along with market analysis and strategies. The program specifically focuses on courses such as market intelligence, consumer behavior, and forecasting. Students who earn a marketing certificate may qualify for careers in a variety of areas like health care, high-technology, and consumer goods and services. President of commercial operations for Mission Pharmacal Company Terrell Herring is an established pharmaceutical marketing executive. In addition to his day job, Terrell “Terry” Herring serves as a board member for several organizations, including BioAgilytix. BioAgilytix provides large molecule global studies performed by researchers from around the world. The company has become a preferred bioanalytical laboratory for many companies in the biotech and pharma fields, offering services in areas such as pharmacokinetics. Pharmacokenetics helps determine how the human body reacts to various pharmaceuticals. This is essential to determining a drug’s safety and effectiveness. The pharmacokinetic assay procedures used by BioAgilytix comply with international regulations and regulatory standards, including FDA guidelines for industry regarding population pharmacokenetics. The population pharmacokenetics process helps identify the differences between - and effectiveness in - a drug’s effect on population subgroups. The FDA guidelines give researchers more information on when a population study should be performed as well as how to execute the study and what parameters to use. Due to constant changes and effectiveness in subgroups, constant communication is required between the FDA review staff and sponsors of a given study. Terrell “Terry” Herring serves as president of commercial operations for the Mission Pharmacal Company in Doylestown, Pennsylvania. Terrell Herring's work in the pharmaceutical industry has won him a place on the prestigious PharmaVOICE 100 on two separate occasions during his career. PharmaVOICE magazine is a leading resource for executives and professionals in the healthcare field. It brings pharmaceutical and biotechnology leaders the latest news on drug development, industry events, and contemporary issues in healthcare and pharmaceuticals. PharmaVOICE also operates the PharmaVOICE 100, a list of the top performers and most inspiring people in the life-sciences field. These awards recognize the men and women who represent their industry well and help solve the major challenges facing stakeholders in the world of biotechnology. Winners are announced each year in the July/August issue of PharmaVOICE. Professionals who have been recognized in multiple years may also be identified as a PharmaVOICE Red Jacket recipient, the publication's highest honor for industry leaders. To view past winners or submit a nomination for the 2018 awards, visit: www.pharmavoice.com. As the president of commercial operations for the Texas-based pharmaceutical company Mission Pharmacal Company, Terrell “Terry” Herring serves as the company's key decision-maker, steering it through an ever-changing economy. During his free time, Terrell Herring enjoys listening to music. Johnny Cash is one of his favorite artists. Considered one of the most influential musicians of the 20th century, Cash passed away in 2003, leaving behind a wealth of timeless hits, one of which was "I Walk the Line." Written in 1956, the tune became his first song to top the Billboard charts. It has since become a classic and is even listed as one of the greatest songs of all time. However, not many people know the story behind the song's composition. In a televised interview with CNN, Cash admitted that he drew inspiration from a tape of Bavarian guitar music being played backward. Cash originally meant for the song to be a slow ballad, but Cash's producer, Sam Phillips, eventually convinced him to use an up-tempo beat that eventually became the singer's signature sound. Twice named among the top 100 inspiring people by PharmaVOICE magazine, Terrell "Terry" Herring has served as president of commercial operations for Mission Pharmacal Company since 2010. Currently residing in Pennsylvania, Terrell "Terry" Herring enjoys both college and professional sports, especially basketball and football. The parallels between sports and business are many yet Herring draws particular inspiration from three main commonalities. First, the importance of working together as a team. It is possible to have the best players and not win a championship. Teams win titles, not players. Being a team is not always enough, however, both in sports and business the best results are achieved by formulating and working to follow a winning game plan. It is important to develop a blueprint for success and actually have a clear vision of how to obtain the desired results. When developing a game plan, it is important to try to factor in any potential obstacles. Inevitably, however, situations can arise that are unexpected and unanticipated. In those instances, it is vitally important to be adaptable. Being able to update plans when roadblocks appear is essential to developing a consistently winning team. All of these attributes can also be applied to business, and Terrell Herring has made that connection and strives to infuse his work life with those three commonalities every day. Based in Doylestown, Pennsylvania, Terrell (“Terry”) Herring guides a number of pharmaceutical industry-focused enterprises within the Mission Family of Companies. Terrell Herring maintains a strong community focus and has long contributed to the fundraising efforts of March for Babies and the March of Dimes. One of the current efforts of the latter nonprofit, which has focused on pregnancy and infant health for generations, is on improving the United States’ track record in preterm birth prevention. While the rates of premature births have decreased over the past decade, this has not extended equally across the country, and residents of “high population/high-burden” areas still experience double-digit levels of preterm birth. The current campaign aims to reduce the rate of preterm births, which stand as a leading cause of infant mortality and lifelong disabilities, to 5.5 percent by 2030. If successful, it will effectively spare 1.3 million babies the health problems associated with premature birth and reduce associated medical cost burdens in ways that benefit society. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|